Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629212 | 0.98 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1LTA4HEGFR | |
| SCHEMBL19634437 | 0.98 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1LTA4HEGFR | |
| SCHEMBL5577016 | 0.95 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LTA4HEGFR | |
| Hydrochloric Acid SCHEMBL4310487 | 0.94 | LTA4H (0.53) | ALDH1A1MAPK1L3MBTL1LTA4HEGFR | |
| SCHEMBL13407447 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1LTA4HEGFR | |
| SCHEMBL18673 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1LMNAMAPT | |
| SCHEMBL8885275 | 0.85 | BCHE (0.52) | ALDH1A1MAPK1L3MBTL1LMNAALOX5 | |
| SCHEMBL2926392 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1LMNAMAPT | |
| SCHEMBL4941879 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1LMNAMAPT | |
| SCHEMBL20624816 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| EP-2569276-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | Protiva Biotherapeutics Inc. (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885MAPK1 4705/4885L3MBTL1 125/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | ALDH1A1 3439/4885MAPK1 4766/4885L3MBTL1 215/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885MAPK1 4596/4885L3MBTL1 222/4885 |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | ALDH1A1 4746/4885MAPK1 4672/4885L3MBTL1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.